Haleon PLC ((GB:HLN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Haleon PLC is conducting a clinical study titled Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice. The study aims to evaluate the effectiveness of a new dentifrice containing stannous fluoride and potassium nitrate in reducing dentin hypersensitivity compared to other dentifrices over an 8-week period.
The intervention being tested is a novel dentifrice combining stannous fluoride and potassium nitrate, designed to reduce tooth sensitivity. This product is compared against three other dentifrices: one with stannous fluoride, one with potassium nitrate, and a placebo.
This Phase 3 study is interventional, with participants randomly assigned to one of four groups. It uses a parallel assignment model and double masking to ensure unbiased results. The primary goal is to assess treatment efficacy.
The study began on October 6, 2025, with the same date marking its latest update. These dates are crucial as they indicate the study’s current recruiting status and recent developments.
The outcome of this study could significantly impact Haleon’s market position by potentially introducing a superior product in the dental care market. This may influence investor sentiment positively, especially if the product proves more effective than competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.